## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.5% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. MRS_5 (7.6%) even more extended - blow-off risk elevated.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($113.87)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. What's Happening With French Biotech Abivax Stock On Wednesday?**
- Source: Benzinga | 20251210T180903 | Bullish | Relevance: 100%
-  Abivax SA's stock is trading higher on Wednesday due to market rumors of a potential takeover by U.S. pharma giant Eli Lilly and Co. The company's stock has surged over 1,500% in the past six months, driven significantly by positive Phase 3 trial results for its ulcerative colitis treatment, obefazimod. Eli Lilly has also been speculated to be preparing for other major acquisitions, including Viking Therapeutics Inc.

**2. Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC**
- Source: MarketBeat | 20251208T111009 | Bullish | Relevance: 99%
-  Kennedy Capital Management LLC increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 7.1% during the second quarter, now owning 241,188 shares valued at $1.85 million. Several other institutional investors also increased their holdings, bringing total institutional ownership to 47.91%. Analysts currently rate Abivax with a "Moderate Buy" and an average target price of $123.00, while the company's lead drug candidate, obefazimod, is in Phase 3 trials for ulcerative colitis.

**3. Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX)**
- Source: MarketBeat | 20251209T160928 | Bullish | Relevance: 98%
-  Abivax (NASDAQ:ABVX) experienced unusually large options trading volume on Tuesday, with traders purchasing 3,575 call options, an 82% increase over the daily average. This activity comes as analysts have raised price targets and ratings, with a consensus "Moderate Buy" rating and an average target of $123. The clinical-stage biotech is advancing its lead drug obefazimod in Phase 3 trials for ulcerative colitis, and its shares traded up about 5.9% to $121.85 amid the increased interest.

**4. Abivax Stock: What Lies Ahead?**
- Source: StocksToTrade | 20251210T020903 | Bullish | Relevance: 98%
-  Abivax SA stock is trending up due to positive sentiment from promising Phase 3 trial results for obefazimod in ulcerative colitis and upcoming Phase 2b data in Crohnâ€™s disease. Analysts have issued a "Buy" rating with a target price of $140, highlighting the drug's unique mechanism and broad immune effects. The company reported strong financial results, including $812M in revenue and $468M in Free Cash Flow, positioning it well for future growth driven by these significant clinical milestones.

**5. French biotech Abivax's shares climb on Eli Lilly bid rumors**
- Source: TradingView | 20251210T130903 | Bullish | Relevance: 98%
-  Shares of French biotech company Abivax (ABVX) surged over 20% on Wednesday due to market rumors suggesting a potential takeover bid by U.S. pharma giant Eli Lilly (LLY). Both companies declined to comment on the speculation, which comes after Abivax reported positive Phase 3 trial results in July for its key drug obefazimod, causing its Paris-listed shares to soar and its market valuation to reach over 8 billion euros.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +16.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.1B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -9.9% to 6.5% (+16.4% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (6.5% > 6.0%), caution on chasing. MRS_5 at 7.6% confirms short-term momentum alignment. Outperforming sector by 10.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.54% (CS: 95) | Strong |
| RSI_14 | 66.0 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 1.091x | Above |
| vs SMA50 | 1.232x | Above |
| vs SMA200 | 2.637x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $127.53
- **Stop Loss:** $113.87 (10.7% risk)
- **Target:** $141.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $4,591.08
- **Portfolio %:** 4.59%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*